Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Deffered Revenue (2021 - 2025)

Historic Non-Current Deffered Revenue for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $1.3 million.

  • ARS Pharmaceuticals' Non-Current Deffered Revenue changed N/A to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Non-Current Deffered Revenue stood at $1.3 million.
  • In the past 5 years, ARS Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $3.0 million in Q4 2021 and a low of $1.1 million during Q2 2025
  • In the last 4 years, ARS Pharmaceuticals' Non-Current Deffered Revenue had a median value of $1.4 million in 2024 and averaged $1.8 million.
  • The largest annual percentage gain for ARS Pharmaceuticals' Non-Current Deffered Revenue in the last 5 years was 473.97% (2022), contrasted with its biggest fall of 473.97% (2022).
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' Non-Current Deffered Revenue stood at $3.0 million in 2021, then fell by 4.74% to $2.9 million in 2022, then crashed by 46.32% to $1.5 million in 2024, then fell by 17.23% to $1.3 million in 2025.
  • Its Non-Current Deffered Revenue was $1.3 million in Q3 2025, compared to $1.1 million in Q2 2025 and $1.3 million in Q1 2025.